# Predilytics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/predilytics

- Industry: Healthcare IT
- Headquarters: Concord, US
- Website: www.predilytics.com
- Total disclosed funding: $19M
- Latest round: Series C (Nov 24, 2014)
- Investors on record: 5

## About

Predilytics, Inc. specializes in healthcare analytics solutions, delivering insights to enhance patient outcomes and optimize healthcare operations through data-driven methodologies.Predilytics, Inc. was founded in 2011 and is based in Concord, US. The company focuses on providing analytics for healthcare management. In 2015, Predilytics was acquired by Welltok, although financial terms were not disclosed. The founder's prior entrepreneurial background is not specified. The total amount raised by Predilytics is USD 8.91 mn through Series C funding led by Qualcomm Ventures, which has contributed to a current company valuation of USD 41.32 mn.Predilytics offers advanced analytics solutions tailored for the healthcare sector, focusing on data integration and predictive modeling. Their services assist healthcare providers in managing patient care effectively by utilizing comprehensive data analysis to improve health outcomes. The client base includes healthcare organizations and insurance companies across North America, Europe, and parts of Asia, aimed at supporting better healthcare decisions and operational efficiencies.The revenue model for Predilytics is based on subscription services, allowing healthcare organizations to access their analytics solutions. Clients typically engage through tiered subscription plans that offer varying levels of service, including advanced data analytics features. Contracts often span multiple years, ensuring a steady revenue stream while fostering long-term partnerships with clients.Predilytics plans to enhance its product offerings by developing new analytics tools aimed at predictive healthcare solutions, with expected launches in the upcoming years. The company is also looking to expand its services into new markets, specifically targeting European regions by 2024. The recent funding through the Series C round will be utilized to support these product developments and market expansions.

## Funding rounds

- Series C, Nov 24, 2014, $8.9M — Highland Capital Partners, Foundation Medical Partners, Flybridge Capital Partners, Qualcomm Ventures
- Series B, Sep 18, 2013, $4.5M — Highland Capital Partners, Foundation Medical Partners, Flybridge Capital Partners, GV
- Series A, Aug 16, 2012, $6.1M — Highland Capital Partners, Flybridge Capital Partners, GV

## Investors

- Highland Capital Partners (https://capitalatlas.ai/funds/highland-capital-partners) — Series A, Series B, Series C
- Flybridge Capital Partners (https://capitalatlas.ai/funds/flybridge-capital-partners) — Series A, Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series B, Series C
- Qualcomm Ventures (https://capitalatlas.ai/funds/qualcomm-ventures) — Series C